Although~50% of acute myeloid leukemia (AML) patients have a normal diploid karyotype by conventional cytogenetics at diagnosis, this patient subset has a variable disease course and outcome. Aberrant overexpression of the p53 protein is usually associated with TP53 alterations and a complex karyotype, but the prevalence and impact of p53 overexpression in AML with diploid cytogenetics is unknown. We examined 100 newly diagnosed AML patients to evaluate the impact of p53 expression status quantified in bone marrow core biopsy samples using immunohistochemistry and computer-assisted image analysis. A total of 24 patients had p53 overexpression defined as 3+ staining intensity in ≥5% of cells; this finding correlated with lower platelet counts (P = .002), absence of CD34 expression in blasts (P = .009), higher bone marrow blast counts (P = .04), and a higher frequency of FLT3 internal tandem duplication (P = .007).
Abstract
Although~50% of acute myeloid leukemia (AML) patients have a normal diploid karyotype by conventional cytogenetics at diagnosis, this patient subset has a variable disease course and outcome. Aberrant overexpression of the p53 protein is usually associated with TP53 alterations and a complex karyotype, but the prevalence and impact of p53 overexpression in AML with diploid cytogenetics is unknown. We examined 100 newly diagnosed AML patients to evaluate the impact of p53 expression status quantified in bone marrow core biopsy samples using immunohistochemistry and computer-assisted image analysis. A total of 24 patients had p53 overexpression defined as 3+ staining intensity in ≥5% of cells; this finding correlated with lower platelet counts (P = .002), absence of CD34 expression in blasts (P = .009), higher bone marrow blast counts (P = .04), and a higher frequency of FLT3 internal tandem duplication (P = .007).
Overexpression of p53 independently predicted for shorter leukemia-free survival in patients who underwent allogeneic stem cell transplantation by univariate (P = .021) and multivariate analyses (P = .004). There was no correlation between MDM2 and p53 protein expression in this cohort. We conclude that p53 expression evaluated by immunohistochemistry in bone marrow biopsy specimens at the time of AML diagnosis may indicate distinct clinical characteristics in patients with normal diploid cytogenetics and is a potentially valuable tool that can enhance risk-stratification.
| INTRODUCTION
TP53 is a tumor suppressor gene located at 17p13 that plays a paramount role as a gatekeeper of genomic integrity and stability. Upon various cellular stresses, including oncogene expression, DNA damage, and hypoxia p53 can be activated and mediates a variety of responses to oppose tumorigenesis. For instance, stabilized p53 induces the transcription of genes mediating cell cycle arrest such as PMAIP1, BBC3, and BAX, thereby sensitizing neoplastic cells to chemotherapy. [1] [2] [3] Defective TP53 is among the most frequently detected abnormalities in human cancers, and can result from mutations, deletions, inactivation of both alleles, loss of heterozygosity, gene rearrangements or unbalanced translocations. 4, 5 In acute myeloid leukemia (AML), TP53 alterations are associated with complex cytogenetics and inferior outcomes, [6] [7] [8] whereas these mutations are rare in patients with seemingly diploid karyotype. 9 The identification of TP53 pathway dysregulation is therefore important for optimal prognostication, stratification and treatment planning of patients with AML.
In clinical practice, copy number alterations are usually detected using conventional karyotyping and fluorescence in situ hybridization, whereas TP53 mutations are increasingly detected by molecular genotyping using next generation sequencing (NGS) assays. Most TP53 genomic alterations cause disruption of p53 protein homeostasis resulting in stabilization and an increased intracellular level of the protein. 10 Such p53 accumulation can be readily detected using immunohistochemistry (IHC). 11, 12 In several solid tumors, IHC staining for p53 has been associated with the presence of missense mutations of TP53 and may identify a subset of patients with worse outcomes. 13 In hematological malignancies, p53 expression has been thoroughly examined in patients with chronic lymphocytic leukemia, myelodysplastic syndromes (MDS), and AML with a complex karyotype and has been found to correlate with shorter survival. 11, 12, 14, 15 We have noted in our practice anecdotal cases of AML with a normal diploid karyotype, also referred to herein as diploid AML, in which p53 is overexpressed at high levels by IHC. However, no systematic analyses surveying p53 expression in diploid AML have been published, and the clinical importance of such observations in this subset of AML patients, regarded otherwise as an intermediate-risk category, 16, 17 remains unclear.
In this study, we evaluated the expression of p53 in a cohort of de novo AML patients with normal diploid karyotype treated at our institution, and we correlated p53 expression status with clinical features and outcomes.
| MATERIALS AND METHODS

| Study group selection
We identified 100 consecutive adult patients with newly diagnosed 
| BM tissue processing and tissue microarray construction
All patients underwent a full diagnostic work-up at the time of presentation that included BM core biopsy, clot preparation, aspirate smears, and touch preparations. BM core biopsy samples were fixed in 10% neutral buffered formaldehyde and decalcified using 10% formic acid for 3 hours at 50 C in a microwave processor. Whole-slide digital scans of TMA p53 IHC slides were acquired using the Aperio ScanScope system and analyzed using the nuclear algorithm of the Aperio ImageScope software (Aperio Technologies, Vista, CA, USA) as described previously in Ref. 20 . 
| Molecular analysis
Mutation profiling was performed using DNA extracted from BM aspirate material using an NGS assay on the Illumina MiSeq sequencer (Illumina, San Diego, CA, USA) as described previously in Ref. In addition, FLT3 (internal tandem duplication [ITD] and D835 mutation) and NPM1 (exon11, codons 283-295) mutations were assessed by polymerase chain reaction (PCR) followed by capillary electrophoresis on the Genetic Analyzer platform (Applied Biosystems, Foster City, CA, USA), as described previously in Ref.
22
. Mutations in TP53 (exons 4-9), IDH1 (exon 4), and IDH2 (exon 4) were also assessed using Sanger sequencing (Applied Biosystems), and mutations in NRAS and KRAS (codons 12, 13, and 61), MPL (codon 515), and JAK2 (codon 617) were detected using pyrosequencing (Biotage, Uppsala, Sweden) in a subset of cases.
| Conventional cytogenetics
Cytogenetic analysis was performed on diagnostic BM aspirate material using standard trypsin-Giemsa banding techniques as described previously in Ref. 23 3 | RESULTS
| Study group characteristics
The baseline characteristics of the study group are summarized in Table 1 In total, 25 of 90 (28%) patients had concomitant NPM1 and FLT3 ITD or mutations. RAS mutations were detected in 16 of 94 (17%) patients.
TP53 was mutated at presentation in 1 of 33 (3%) patients analyzed;
this mutation rate was comparable to that seen in a historical cohort of 310 patients with diploid de novo AML seen at our institution, among whom 8 (2.5%) had TP53 mutation at presentation. (Supporting Information Table S1 and Supporting Information Figure S1 ). 
| P53 expression in diploid AML
We first set out to determine a clinically relevant cut-off for p53 overexpression by IHC (Figure 1 ), taking into account the standard use of 5% mutant allelic frequency in clinical settings where TP53 mutational status is evaluated, as well as previous reports of p53 expression in AML. 25, 26 We explored various cutoffs, including 3%, 5%, and 10% using 3+ intensity alone as well as the combination of 3+ and 2+.
Based on these analyses, we identified 3+ p53 expression in ≥5% of cellularity as a clinically meaningful cut-off, henceforth designated p53 high (Supporting Information Figure S2 ). All lower and negative expression levels were designated as p53 low . In total, 24% of the AML patients in this study group were designated as p53 1.6-2.2). None of the cases in this study had a total lack of p53 expression that would suggest the presence of a truncating mutation. 
| Clinical correlates of TP53 overexpression in AML with diploid karyotype
The clinical and pathological features of the p53 high and p53 low groups are summarized and compared in Table 2 . Patients in the p53 high group had lower platelet counts (P = .002), a lower frequency of CD34 expression in blasts (P = .009), higher BM blast counts (P = .04), and higher serum lactate dehydrogenase (LDH) levels (P = .009). Notably, patients in the p53 high group had higher FLT3-ITD mutation rates compared with those in the p53 low group (63% vs 28%; P = .002). There was no significant difference between the p53 high and p53 low cohorts with respect to age, gender, and other complete blood count parameters. We performed multivariate analysis using Cox regression with backward (Wald) stepwise elimination of prognostic factors to assess the independent impact of potential baseline variables on OS. The initial model included age at diagnosis, gender, presence of FLT3-ITD and NPM1 mutations, and p53 high status. We found that only age (P = .002) independently correlated with shorter OS although the presence of FLT3-ITD showed a trend (P = .056) for shorter OS. We then removed the p53 high group as a potential confounding factor and found that age (P = .002) and FLT3-ITD mutation (P = .043) were significantly associated with shorter OS. In the next analysis, we excluded gender as a possible confounding factor and again found that only age (P = .003) and FLT3-ITD (P = .044) remained independently associated with shorter OS. In the final stage of analysis, we removed NPM1 mutational status and found that age (P = .005)
remained an independent predictor of shorter OS, whereas the presence of FLT3-ITD in these patients showed only a trend towards shorter OS (P = .069). Based on the combination of analyses used in this stepwise elimination method, we concluded that only age (P = .005) is an independent predictor factor of OS in this cohort of patients. Notably, in a similar analysis using LFS as the endpoint, p53 high status correlated independently with shorter LFS among patients who underwent allo-SCT (P = .004; HR = 6.142; 95% CI:
1.76-21.38).
| DISCUSSION
To the best of our knowledge, this study is the first to evaluate the prognostic impact of p53 protein expression status in de novo AML patients with a normal diploid karyotype. We show an independent association between p53 overexpression and shorter LFS in this disease subset. IHC is a rapid, cost-effective method that is standardized, reproducible, and readily available for routine use. In addition to detection of somatic mutations, identifying strong p53 stabilization and expression reflects p53 pathway aberration(s) and potentially can be used to refine prognostication of patients and optimization of treatment options.
In de novo AML, TP53 mutations have been reported in 5%-8%
of patients, [27] [28] [29] and universally have been shown to correlate with complex karyotypes and poorer outcomes. 28 TP53 mutations often lead to elevated steady state levels of mutant p53 protein, due to a lack of p53-inducible proteins, such as the E-3 ubiquitin ligase MDM2, to promote p53 degradation. 30, 31 Dampened p53 function can also be found in the setting of wild-type TP53, mostly through high levels of canonical negative regulators of p53, amplification of MDM2 and MDM4 with consequent overexpression of MDM2 and MDM4 proteins, or through p14ARF inactivation. [32] [33] [34] In earlier studies of AML and MDS, 20, 35, 36 p53 overexpression detected by IHC was found to be associated with TP53 mutation and inferior survival. More recently, a study by Kornblau et al. 37 conducted on a large cohort of 511 AML patients using reverse phase protein array technology showed frequent p53 pathway disruption in AML patients with wild-type TP53.
Importantly, around 30% of these patients had high levels of MDM2 in the setting of wild-type TP53. Furthermore, patients with MDM2 amplification exhibited a dismal prognosis similar to patients with TP53 mutations. Indeed, nutlin reduced cell viability in leukemia cells overexpressing MDM2 in the presence of wild type TP53, indicating that inhibiting the MDM2-p53 axis is a strategy of potential clinical value. While a role for MDM2 cannot be excluded in patients with diploid de novo p53 high AML, our data showed no correlation between p53 and MDM2 expression, warranting further exploration of immediate p53 regulators such as MDM4 or, given the poorly sensitive IHC studies for MDM2 and MDM4, using more sensitive assays for detecting expression of these proteins.
NPM1, a molecular chaperone linked to favorable prognosis in AML, 38 was the most commonly mutated gene in this study with a frequency of 49%, followed by 48% for FLT3 including both ITD and point mutations. FLT3 and NMP1 mutations occurred together in 28% of cases. In patients with p53 high expression, FLT3 and NPM1 were mutated in 67% and 54%, respectively, and they were comutated in 33% of patients. FLT3 and NPM1 mutations are strongly associated with AML and diploid cytogenetics. 39, 40 In a study by Haferlach et al. 9 that assessed the frequency of TP53 mutations in 235 AML patients, TP53 and FLT3 mutations were rarely detected concomitantly, whereas NPM1 and TP53 mutations were not observed in the same patient. 41 However, a number of studies have shown that wild-type (data not shown). The cutoff for p53 overexpression has ranged from ≥1% to ≥10% in various studies. 12, 20, 35 In this study, a cutoff of ≥5% provided the best overall predictive value. We acknowledge that one of the limitations of this study is an insufficient number of cases with TP53 mutation to generate a receiver-operator curve with adequate statistical power. TP53 mutational status was available in 33 (33%) samples and mutations were detected in 3 (9%) of these cases.
Accordingly, although the cut-off of ≥5% 3+ was prognostic in our dataset, validation in larger study cohorts will be valuable.
We further analyzed survival outcomes according to p53 expression level and found that the median LFS was significantly shorter in the subset of patients with p53 overexpression (9 vs 55 months; P = .026), including those who were consolidated with allo-SCT. This observation suggests that p53 expression level as assessed by IHC could be helpful to stratify patients with AML and a diploid karyotype, currently classified as intermediate-risk disease. P53 expression level also could help to identify patients who could possibly benefit from postSCT maintenance therapy.
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